Evidence map›Paper›PMID 42723906›Full record

ArticleTranslational lung cancer research2026

Osimertinib

Tae Hata, Tadaaki Yamada, Koji Mikami, Toshihide Yokoyama, Tomohiro Oba, Yasuhiro Goto, Naoki Furuya, Shun Futamura, Hirokazu Taniguchi, Tamio Okimoto and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Tae HataDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID https://orcid.org/0000-0002-0598-2280
Tadaaki YamadaDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID https://orcid.org/0000-0002-6945-281X
Koji MikamiDepartment of Respiratory Medicine and Hematology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan.
Toshihide YokoyamaDepartment of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan.
Tomohiro ObaDepartment of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.
Yasuhiro GotoDepartment of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Japan.
Naoki FuruyaDepartment of Respiratory Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Shun FutamuraDepartment of Respiratory Medicine, Osaka International Cancer Institute, Osaka, Japan.
Hirokazu TaniguchiClinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan.
Tamio OkimotoDivision of Medical Oncology & Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan.
Soichi HiraiDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Sayaka UdaDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Asuka OkadaDepartment of Respiratory Medicine, Saiseikai Suita Hospital, Suita, Japan.
Rie WatanabeDepartment of Respiratory Medicine, Fukuchiyama City Hospital, Fukuchiyama, Japan.
Naoko IshizakiDepartment of Respiratory Medicine, Uji-Tokushukai Medical Center, Uji, Japan.
Hayato KawachiDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takashi KijimaDepartment of Respiratory Medicine and Hematology, School of Medicine, Hyogo Medical University, Nishinomiya, Japan.
Koichi TakayamaDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Osimertinib is the standard first-line treatment for non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor ( Methods: This multicenter retrospective cohort study analyzed longitudinal medical records of patients with advanced or recurrent Results: Among 421 patients (median age, 73 years; 65% female; 66% never-smokers; 99% adenocarcinoma), 373 received osimertinib and 48 received erlotinib+A. In the multivariable Cox regression analysis, no significant differences were observed between the osimertinib and erlotinib+A groups in MPE-PFS [adjusted hazard ratio (HR): 0.79; 95% confidence interval (CI): 0.54-1.15; P=0.22], PFS (adjusted HR: 0.87; 95% CI: 0.60-1.25; P=0.45), or OS (adjusted HR: 0.95; 95% CI: 0.63-1.44; P=0.83). However, a significant interaction between the treatment regimen and Conclusions: Osimertinib showed comparable efficacy to erlotinib+A in MPE control with a more favorable safety profile. Subgroup analysis suggested a particular benefit in patients harboring

Indexed as

angiogenesis inhibitorepidermal growth factor receptor (EGFR)Non-small cell lung cancer (NSCLC)osimertinibpleural effusion

Identifiers

PMID42723906
PMCPMC13557903

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.